Stem Cell Transplant and Cellular Therapy. Tweets, Retweets, and Likes are based on my own opinion and not medical advice.
Joined April 2014
- Tweets1.7K
- Following563
- Followers423
- Likes6K
Jeremy Ramdial retweeted
What is Measurable Residual Disease #MRD❓
🟰 Hidden part of the iceberg ❄️
👀 Minimal disease left behind leading to disease relapse 🤕
💊 New strategies available to treat MRD and cure #Leukemia 👊
#bloodcancer #cancerawareness #endcancer – at West University Place, TX
Congrats Rohtesh Mehta!! of @MDAndersonNews on
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide jamanetwork.com/journals/jam…
Jeremy Ramdial retweeted
Dr. Garcia-Manero and @DrHKantarjian discuss the VERONA trial at #SOHO2025. Stay tuned for more at SOHO Insider
Dr Uday Popat presenting data on the role of SCT for patients with Int and High risk MDS. #MPNsm #MDS #SOHO2025 @MDAndersonNews
Please stop by poster CT 654 tonite at 6:30pm to discuss with Dr @dr_PrakhyathS his meta-analysis comparing two Cellular therapy options for patients with #MMsm .
#SOHO2025 @SocietyofHemOnc
Jeremy Ramdial retweeted
🔬 HCT in MDS – Holistic Decision Process (SOHO 2025)
🧩 Decision factors:
•⚰️ Mortality
•🏥 Morbidity
•🧬 Prognosis
•🧑⚕️ Patient views
•🎂 Age & comorbidities
•🧑🤝🧑 Donor availability
📊 Key insights (IPSS-M based):
•Early transplant benefits Moderate-high, High, and Very High risk MDS patients.
•Age matters → younger (<55y) benefit most, but even 55–65y group shows survival advantage.
•Some Low/Moderate-low risk may benefit if:
•Progressive cytopenias
•Transfusion dependence
•Failure of HMA
⚠️ Limitations: retrospective data, need for prospective validation.
#MDS #BMT #Transplant #IPSSM #soho25
Jeremy Ramdial retweeted
Among patients with myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blockers led to a lower risk of death or major cardiovascular events than no beta-blocker therapy. Full BETAMI–DANBLOCK trial results and Research Summary: nej.md/4oT6aSg
ALT The New England Journal of Medicine Beta-Blockers after MI in Patients without Heart Failure A Research Summary based on Munkhaugen J et al. | 10.1056/NEJMoa2505985 | Published on August 30, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Jeremy Ramdial retweeted
Out in @Ajhematology: Relapse mechanisms after frontline FLT3 inhibitor therapy in FLT3 #AML include FLT3 loss and emergent non-FLT3 mutations. Post-relapse outcomes are poor, especially in FLT3 mut relapses.
@NicholasShortMD #Leukemia
doi.org/10.1002/ajh.70053
#leusm
Jeremy Ramdial retweeted
Survival of adult #ALL is significantly better 👍
‼️ Ph ➖ ALL: Adding antibodies & immunotherapy is crucial, in frontline & salvage
‼️ Ph➕ ALL: Chemotherapy-free approach improves survival & spares transplant
#leusm @DrHKantarjian @SocietyofHemOnc @OncoAlert
Jeremy Ramdial retweeted
We're proud to support @lcalsfeld for LLS Visionary of the Year! ❤️
A true advocate for the cancer community, Clark is making a difference—and there’s still time to support his campaign before June 14!
Donate here: tinyurl.com/calsfeld
#CancerAdvocacy #VisionaryOfTheYear
Jeremy Ramdial retweeted
Please check out our paper published today in Nature that identifies CREM as a key checkpoint limiting CAR NK cell function.CRISPR knockout of CREM significantly enhanced anti-tumor activity, implicating a broader role in NK cell regulation. Huge congrats to @hindrafei and our
Jeremy Ramdial retweeted
🧵1/
T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓.
📄Link: nature.com/articles/s41586-0…
I’m so thrilled🥳to share our work out now🚨@Nature identifying🔎CREM as a central intracellular checkpoint🚦in #CARNK cells.
Let me tell you a story...👇🏼
Jeremy Ramdial retweeted
Discussing the latest updates in Chronic Myeloid Leukemia #CML at HemOnc Pulse meeting
✅ Looking for ways to improve #patient outcomes & access to treatment
✅ Panel discussion & insights on next steps in the field
✅ Connecting with colleagues & friends
#HOPlive25 #leusm
Jeremy Ramdial retweeted
Dr. @Jeremy_Ramdial shared details of a Phase II study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies that began enrolling in December 2024. @ASCO #ASCO25 #EndCancer
ALT Dr. Jeremy Ramdial with his poster at ASCO 2025
Jeremy Ramdial retweeted
The all-oral combination of revumenib with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) results in high remission rates in patients with relapsed/refractory AML with certain genetic mutations, our Dr. @GhayasIssa reported. #ASH24 #EndCancer
ALT Ghayas Issa presenting at ASH 2024
Jeremy Ramdial retweeted
CONGRESS | #ASH24 | PRESENTATION
@GhayasIssa @MDAndersonNews presents results from the phase I/II SAVE trial of revumenib plus ASTX727 and venetoclax in pediatric and adult patients with R/R AML.
This all-oral regimen demonstrated high response rates, with an ORR of 82%, and an acceptable safety profile in heavily pretreated patients with R/R KMT2Ar, NPM1 mutated, or NUP98r AML.
Follow our live feed for more updates: aml-hub.com/medical-informat…
#leusm #AMLsm #MedicalCongress
Jeremy Ramdial retweeted
What are the latest advances in stem cell transplants? Stop by #ASH24 booth 1949 at 12:30 PT to learn from Drs. Gheath Al-Atrash and Uday Popat. (1/5) #EndCancer
ALT Meet the Experts Advances in stem cell transplants Booth 1949